Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus PROFENAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus PROFENAL.
ANAPROX DS vs PROFENAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
600 mg orally every 6 to 8 hours as needed for pain; or 1000 mg orally every 6 to 8 hours for antipyresis; maximum single dose 1000 mg, maximum daily dose 4000 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
6-8 hours (terminal); requires dosing every 6-8 hours to maintain therapeutic levels
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Primarily renal (approximately 70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category C
Category C
NSAID
NSAID